37 results
424B5
VCNX
Vaccinex Inc
28 Mar 24
Prospectus supplement for primary offering
1:27pm
technologies which have potential to develop product candidates against novel targets that could address serious diseases or conditions that have
8-K
EX-99.1
VCNX
Vaccinex Inc
21 Feb 24
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
10:10am
against challenging multi-pass membrane targets
ROCHESTER, N.Y., February 21, 2024 –Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology … transmembrane protein targets.
Within the last 3 months, Vaccinex has entered into new antibody discovery agreements for complex targets with 3 major pharma
8-K
EX-99.1
VCNX
Vaccinex Inc
26 Sep 23
Regulation FD Disclosure
8:06am
with Clinical Outcome” will be a podium presentation at the Keystone Symposia, B Cells and Tertiary Lymphoid Structures: Emerging Targets in Cancer
8-K
t34ze 9ir0r1oi2
26 Sep 23
Regulation FD Disclosure
8:06am
424B5
7wi5xk gfo
19 May 23
Prospectus supplement for primary offering
5:13pm
8-K
EX-99.2
x26wwibb
1 Aug 22
Regulation FD Disclosure
8:01am
8-K
EX-99.1
qma7bt3s42 42qvv3
10 Jun 22
Regulation FD Disclosure
8:01am
424B3
yy97l dm4do0r2pzugsh
29 Apr 22
Prospectus supplement
4:16pm
8-K
EX-99.1
v1dkhbv80zn8eoe9
19 Feb 21
Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical
1:07pm
8-K
EX-99.1
tbu7 v4ejrrv9zagpg70
22 Sep 20
Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab
7:40am
424B5
xm7ibrw1
9 Sep 20
Prospectus supplement for primary offering
4:52pm
424B5
32g i8eva8dpjwb
14 Aug 20
Prospectus supplement for primary offering
4:28pm
424B5
1467g58x2v6 8jeow
27 Mar 20
Prospectus supplement for primary offering
5:05pm